Description
🖼️ Tool Name:
Nabla Bio
🔖 Tool Category:
AI-powered biologics / drug design platform; it falls under Integrations & APIs and Forecasting & Applied ML / Analytics & Dashboards in the biotech domain.
✏️ What does this tool offer?
Nabla Bio builds a platform, centered on their Joint Atomic Model (JAM), that uses generative AI and integrated experimental systems to design protein-based therapeutics (e.g. antibodies, multispecific biologics) de novo.
It “autocomplete” molecular designs given partial context (e.g. a disease target or epitope) and optimizes for developability, binding, and function.
They integrate both in silico modeling and human-relevant lab testing to sharpen model predictions.
⭐ What does the tool actually deliver based on user experience?
• Generation of high-quality antibody or biologic candidates in weeks instead of months or years.
• Ability to explore hard targets (e.g. membrane proteins) and multispecific architectures.
• Measured experimental validation (binding, developability, cellular/in vivo) tightly coupled with model training.
• Collaboration with pharma partners (e.g. Takeda) to deploy JAM in early-stage drug pipelines.
🤖 Does it include automation?
Yes — the platform automates molecular generation, optimization, and iterative feedback loops with lab data, thus reducing manual trial & error in biologics design.
💰 Pricing Model:
Custom / enterprise / partnership-based (not publicly disclosed).
🆓 Free Plan Details:
None publicly documented.
💳 Paid Plan Details:
Access to JAM, biologics campaign support, integrations, scaling, and joint research partnerships.
🧭 Access Method:
• Via platform / partnership with Nabla Bio.
• Integration into pharmaceutical R&D pipelines.
• Likely via APIs or collaboration contracts.
🔗 Experience Link:
https://www.nabla.bio